RTP Mobile Logo
Select Publications

Burger JA et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia 2020;34(3):787-98. Abstract

Byrd JC et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med 2016;374:323-32. Abstract

Fischer K et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med 2019;380(23):2225-36. Abstract

Furman RR et al. Ibrutinib resistance in chronic lymphocytic leukemia. N Engl J Med 2014;370(24):2352-4. Abstract

Liu E et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020;382(6):545-53. Abstract

Mihalyova J et al. Venetoclax: A new wave in hematooncology. Exp Hematol 2018;61:10-25. Abstract

Moreno C et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2019;20(1):43-56. Abstract

O’Brien S et al. Single-agent ibrutinib in treatment-na├»ve and relapsed/refractory chronic lymphocytic leukemia: A 5-year experience. Blood 2018;131(17):1910-9. Abstract

Shanafelt TD et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381(5):432-43. Abstract

Shanafelt TD et al. Ibrutinib and rituximab provides superior clinical outcome compared to FCR in younger patients with chronic lymphocytic leukemia (CLL): Extended follow-up from the E1912 trial. ASH 2019;Abstract 33.

Sharman JP et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet 2020;395(10232):1278-91. Abstract

Siddiqi T et al. Rapid undetectable MRD (uMRD) responses in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) treated with lisocabtagene maraleucel (liso-cel), a CD19-directed CAR T cell product: Updated results from Transcend CLL 004, a phase 1/2 study including patients with high-risk disease previously treated with ibrutinib. ASH 2019;Abstract 642.

Woyach JA et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med 2018;379(26):2517-28. Abstract